Hemab Therapeutics Shares Promising Data for Bleeding Disorder Treatments

Hemab Therapeutics unveiled new clinical findings for HMB-002, showing positive preliminary results in treating Von Willebrand disease, with most patients experiencing no treated bleeds after dosing. The company also introduced HMB-003, a potential monthly treatment for heavy menstrual bleeding, based on encouraging nonclinical studies.